title: Efficacy and durability of radiofrequency ablation for Barrett's Esophagus: systematic review and meta-analysis.
abstract: OBJECTIVE
  In patients with Barrett's esophagus (BE), radiofrequency ablation (RFA) safely and effectively eradicates dysplasia and intestinal metaplasia. We aimed to determine the efficacy and durability of RFA for patients with dysplastic and nondysplastic BE.
  
  
  METHODS
  We performed a systematic review and meta-analysis of studies identified in PubMed and EMBASE that reported the proportion of patients treated with RFA who had complete eradication of dysplasia (CE-D) and intestinal metaplasia (CE-IM), and the proportion of patients with recurrent IM after successful treatment. Pooled estimates of CE-D, CE-IM, IM recurrence, and adverse events were calculated.
  
  
  RESULTS
  We identified 18 studies of 3802 patients reporting efficacy and 6 studies of 540 patients reporting durability. Ten were prospective cohort studies, 9 were retrospective cohort studies, and 1 was a randomized trial. CE-IM was achieved in 78% of patients (95% confidence interval [CI], 70%-86%) and CE-D was achieved in 91% (95% CI, 87%-95%). After eradication, IM recurred in 13% (95% CI, 9%-18%). Progression to cancer occurred in 0.2% of patients during treatment and in 0.7% of those after CE-IM. Esophageal stricture was the most common adverse event and was reported in 5% of patients (95% CI, 3%-7%). Confidence in most summary estimates was limited by a high degree of heterogeneity, which did not appear to be caused by single outlier studies.
  
  
  CONCLUSIONS
  Treatment of BE with RFA results in CE-D and CE-IM in a high proportion of patients, with few recurrences of IM after treatment and a low rate of adverse events. Despite the large amount of study heterogeneity, these data provide additional information for patients and providers to make informed treatment decisions.
authors: Center for Esophageal Diseases and Swallowing, Division of Gastroenterology and Hepatology, Department of Medicine, University of North Carolina, Chapel Hill, North Carolina.
authors: Eric S
authors: ES
authors: Orman
authors: Nan
authors: N
authors: Li
authors: Nicholas J
authors: NJ
authors: Shaheen
mesh_terms: D001471:Barrett Esophagus / Q000601:surgery*; D017115:Catheter Ablation / Q000009:adverse effects / Q000379:methods*; D006801:Humans; D012008:Recurrence; D016896:Treatment Outcome
keywords: AIM; Ablation of Intestinal Metaplasia; BE; Barrett's esophagus; CE-D; CE-IM; CI; EAC; EMR; Endoscopy; Esophageal Cancer; Gastroesophageal Reflux; HGD; IM; IMC; LGD; NDBE; Prevention; RCT; RFA; RR; complete eradication of dysplasia; complete eradication of intestinal metaplasia; confidence interval; endoscopic mucosal resection; esophageal adenocarcinoma; high-grade dysplasia; intestinal metaplasia; intramucosal carcinoma; low-grade dysplasia; nondysplastic Barrett's esophagus; radiofrequency ablation; randomized controlled trial; risk ratio
references: Stat Med. 2002 Jun 15;21(11):1539-58
references: 12111919
references: Gastrointest Endosc. 2011 Oct;74(4):753-60
references: 21820109
references: Clin Gastroenterol Hepatol. 2012 Feb;10(2):150-4
references: 22056303
references: Gastrointest Endosc. 1999 Jan;49(1):1-7
references: 9869715
references: Surg Endosc. 2009 Oct;23(10):2175-80
references: 19263139
references: Gastrointest Endosc. 2005 Oct;62(4):488-98
references: 16185958
references: Am J Gastroenterol. 2009 Feb;104(2):502-13
references: 19174812
references: Endoscopy. 2010 Apr;42(4):272-8
references: 20146164
references: Clin Gastroenterol Hepatol. 2006 May;4(5):566-72
references: 16630761
references: Gastrointest Endosc. 2008 Nov;68(5):867-76
references: 18561930
references: Gastrointest Endosc. 2004 Dec;60(6):1002-10
references: 15605025
references: Endoscopy. 2010 Oct;42(10):781-9
references: 20857372
references: Control Clin Trials. 1986 Sep;7(3):177-88
references: 3802833
references: Am Surg. 2012 Jul;78(7):774-8
references: 22748537
references: Clin Res Hepatol Gastroenterol. 2012 Aug;36(4):371-7
references: 22361442
references: Gastroenterology. 2011 Aug;141(2):460-8
references: 21679712
references: Gastrointest Endosc. 2011 Apr;73(4):682-90
references: 21292262
references: Am J Gastroenterol. 2009 Feb;104(2):310-7
references: 19174783
references: J Epidemiol Community Health. 1998 Jun;52(6):377-84
references: 9764259
references: Gastrointest Endosc. 2008 Apr;67(4):604-9
references: 18155214
references: Gastrointest Endosc. 2007 Feb;65(2):185-95
references: 17258973
references: Gastroenterology. 2011 Mar;140(3):1084-91
references: 21376940
references: Am J Gastroenterol. 2013 Feb;108(2):187-95; quiz 196
references: 23247578
references: Gut. 2002 Dec;51(6):776-80
references: 12427775
references: Gastrointest Endosc. 2010 Apr;71(4):680-5
references: 20363409
references: Dig Dis Sci. 2012 Oct;57(10):2625-32
references: 22878916
references: JAMA. 2000 Apr 19;283(15):2008-12
references: 10789670
references: Am J Gastroenterol. 2011 Jul;106(7):1231-8
references: 21577245
references: Clin Gastroenterol Hepatol. 2013 Jun;11(6):636-42
references: 23103824
references: BMC Med Res Methodol. 2009 Dec 04;9:80
references: 19961608
references: Clin Gastroenterol Hepatol. 2010 Jan;8(1):23-9
references: 19602454
references: N Engl J Med. 2011 Oct 13;365(15):1375-83
references: 21995385
references: Gastroenterology. 2012 Sep;143(3):576-581
references: 22609385
references: Gastroenterology. 2005 Dec;129(6):1825-31
references: 16344051
references: N Engl J Med. 2009 May 28;360(22):2277-88
references: 19474425
references: Gut. 2011 Jun;60(6):765-73
references: 21209124